Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics-Reference-Cited by-同舟云学术

Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics

Published:2009-05 Issue:2 Volume:131 Page:189-201
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

De Groot Anne S.,Martin William

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference51 articles.

1. Committee for Medicinal Products for Human Use (CHMP). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins, Doc. Ref. EMEA/CHMP/BMWP/14327/2006, London, 2007

2. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products;Mire-Sluis;J. Immunol. Methods,2004

3. Immunogenicity of protein therapeutics;De Groot;Trends Immunol.,2007

4. Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein;Koren;Clin. Immunol.,2007

5. Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses;Barbosa;Drug Discov. Today,2007

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biobetters: IFN-α2b Variants with Reduced Immunogenicity for the Treatment of Human Viral Diseases;Infectious Diseases;2023-12-20

2. Does human homology reduce the potential immunogenicity of non-antibody scaffolds?;Frontiers in Immunology;2023-11-07

3. Immunogenicity risk assessment of synthetic peptide drugs and their impurities;Drug Discovery Today;2023-10

4. Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning;Nature Biomedical Engineering;2023-09-04

5. Identification of immunodominant T cell epitopes induced by natural Zika virus infection;Frontiers in Immunology;2023-08-29